Absorption Systems Becomes Society of Toxicology Affiliate
News Mar 02, 2010
Absorption Systems has joined the Society of Toxicology, the global professional association of toxicologists, as an SOT Affiliate.
The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing. Absorption Systems had focused on ADME testing for years, and broadened its portfolio of services to include toxicology through the mid-2009 acquisition of an AAALAC-accredited GLP toxicology testing facility in San Diego, CA.
Absorption Systems pioneered the Caco-2 cell model for in vitro prediction of oral drug absorption. Today, the 100-person company offers a broad service portfolio, including in vitro, in situ and in vivo models to assess the ADMET properties of small molecules.
Additionally, Absorption Systems provides in vivo testing of the safety and efficacy of both small molecule drugs and biologics, medical devices, cardiovascular and CNS pharmacology, diabetes, psoriasis and neutropenia.
“Absorption Systems is proud to become an affiliate of the Society of Toxicology and will work to contribute to the organization’s continued success,” said Dr. Sarath Kanekal, Absorption Systems’ Vice President of Pharmacology and Toxicology and an SOT member for over 20 years.
“Absorption Systems has long been active in helping drug companies more rapidly advance candidates to clinical testing. Now we have added toxicology to that toolkit. We believe that by joining with others in industry and research, we can make a greater impact in helping our customers better appreciate the importance of conducting high-quality, regulatory-driven toxicology studies.”
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE